Reckitt Benckiser Group (OTCMKTS:RBGLY) Upgraded at Barclays

Barclays upgraded shares of Reckitt Benckiser Group (OTCMKTS:RBGLY) from a hold rating to a strong-buy rating in a report published on Monday,Zacks.com reports.

RBGLY has been the subject of a number of other reports. Royal Bank Of Canada reissued an “outperform” rating on shares of Reckitt Benckiser Group in a research note on Thursday, October 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Reckitt Benckiser Group in a report on Monday, October 27th. Three research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Reckitt Benckiser Group currently has an average rating of “Buy”.

Reckitt Benckiser Group Stock Performance

RBGLY opened at $15.89 on Monday. The firm has a 50-day simple moving average of $15.47 and a two-hundred day simple moving average of $14.78. The company has a debt-to-equity ratio of 1.01, a current ratio of 0.56 and a quick ratio of 0.37. Reckitt Benckiser Group has a 52 week low of $11.73 and a 52 week high of $15.98.

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.